Close Menu

NEW YORK – Despite broader market downturns, demand for PCR-, rapid antigen-, and antibody-based SARS-CoV-2 tests drove significant increases in share price for many diagnostic firms throughout the first half of 2020.

The 360Dx Index increased 17 percent from December 2019 to June 2020, with multiple firms seeing share price jumps of 100 percent or more. In contrast, the Dow Jones Industrial Average decreased 10 percent over the same period, although the Nasdaq grew 12 percent, and the Nasdaq Biotechnology Index leapt 14 percent in the first half of the year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.